Private Equity
Stratify for Private Equity
Evaluating AI capital deployment risk across portfolio companies before investment approval.
Portfolio Risk
AI Capital Risk in Portfolio Companies
Private equity firms increasingly evaluate AI initiatives across portfolio companies and require a structured exposure evaluation before approving capital deployment. The instrument provides a consistent method to assess governance, regulatory, data, execution, and capital discipline conditions before board and investment committee authorization decisions.
Application
How Private Equity Firms Use the Instrument
Operating partners and investment committees use the Stratify AI Capital Risk Instrument to evaluate AI readiness, surface exposure conditions, and generate capital authorization determinations before approving AI capital commitments across portfolio entities.
Visibility
Portfolio-Level Visibility
Running the instrument across multiple portfolio companies provides portfolio-wide visibility into AI capital exposure, allowing firms to compare readiness conditions, identify constrained deployment paths, and prioritize remediation where risk concentration is highest.
Portfolio Analysis
Portfolio AI Capital Exposure Map
When the Stratify AI Capital Risk Instrument is applied across multiple portfolio companies, it produces portfolio-level visibility into AI capital exposure and authorization readiness.
Operating partners can identify companies prepared for AI deployment, companies requiring governance remediation, and the sequencing of AI capital deployment across the portfolio.
| Portfolio Company | AI Capital Risk Index (ACRI) | Authorization Posture | Primary Exposure Vector |
|---|---|---|---|
| Portfolio Company A | 72 | Pause | Governance |
| Portfolio Company B | 55 | Controlled Investment | Regulatory |
| Portfolio Company C | 29 | Authorize Deployment | Execution |
Typical Scope
Typical Portfolio Company Evaluation
Typical Investment Range
$1M–$10M
Evaluation Timeline
~14 days